9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Estimated reading time: < 1 min

Condition: Lung Cancer

Estimated Enrollment: 18

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Maximum Tolerated Dose (MTD),  safety,  detection of virus in body fluids, evaluation of viral appearance in tumor

Interventions: GL-ONC1,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 2020

Completion Date: January 2020

Last  Posted Date: January 18, 2019

Location: Memorial Sloan Kettering Cancer Center, New York, New York, United States

Website Link: https://ClinicalTrials.gov/show/NCT01766739

Was this article helpful?
Dislike 0